Strategic partnerships Kemp Proteins has a track record of forming strategic partnerships with industry players (Columbia Biosciences, OneCyte Biotechnologies, Avivo Biomedical) and notes ongoing collaborations to advance process optimization, indicating a fertile landscape for co-development deals and expanded service scopes.

Biologics and antibodies With core expertise in gene-to-protein expression, monoclonal antibodies, and protein complexes across mammalian, insect, and bacterial systems, target opportunities include antibody development, protein production scale-up, and assay development for biotech and pharma customers.

Regulatory readiness ISO 9001 and ISO 13485 certification, AAALAC accreditation, and GMP-aligned transition capabilities suggest Kemp Proteins can support clients aiming for regulated preclinical manufacturing, increasing appeal to firms pursuing compliance-heavy programs.

In silico to in vitro Recent collaborations emphasize integrating predictive design with rapid experimental validation, signaling demand for combined computational design and high-throughput experimentation services to accelerate discovery-to-manufacturing timelines.

Mid-market growth Revenue range ($10M–$25M) and a focused, specialized service footprint position Kemp Proteins as a compelling partner for mid-market biotech firms seeking boutique, customizable protein services without the scale of large CROs.